Home Top News Harmony Biosciences to acquire Main Line’s Zynerba in up to $200M deal Top News Harmony Biosciences to acquire Main Line’s Zynerba in up to $200M deal By - August 14, 2023 0 16 Facebook Twitter Pinterest WhatsApp [#item_full_content] RELATED ARTICLESMORE FROM AUTHOR Market Digest: CHH, CPB, KBH, MDT Some Schwab Customers Say They Want Their TD Ameritrade App Back Analyst Report: KB Home LEAVE A REPLY Cancel reply Please enter your comment! Please enter your name here You have entered an incorrect email address! Please enter your email address here Save my name, email, and website in this browser for the next time I comment. One Company Is Expected To Grow Even Faster Than Nvidia These 12 Stocks Could Be Takeover Targets in 2022 Stocks moving after hours: United, Interactive Brokers, Moderna Stock market news live updates: Stock futures rise to extend gains... Ask an Advisor: I’m Way Behind on Retirement Savings. What Do...
